Cytosorbents Corporation (CTSO)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CTSO Insider Trading Activity
CTSO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $47,269 | 3 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| MARIANI PETER J | Chief Financial Officer | 3 | $47,269 | 0 | $0 | $47,269 |
About Cytosorbents Corporation
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Insider Activity of Cytosorbents Corporation
Over the last 12 months, insiders at Cytosorbents Corporation have bought $47,269 and sold $0 worth of Cytosorbents Corporation stock.
On average, over the past 5 years, insiders at Cytosorbents Corporation have bought $164,018 and sold $100,796 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MARIANI PETER J (Chief Financial Officer) — $47,269.
The last purchase of 20,000 shares for transaction amount of $19,294 was made by MARIANI PETER J (Chief Financial Officer) on 2024‑12‑13.
List of Insider Buy and Sell Transactions, Cytosorbents Corporation
| 2024-12-13 | MARIANI PETER J | Chief Financial Officer | 20,000 0.0335% | $0.96 | $19,294 | +1.98% | ||
| 2024-12-12 | MARIANI PETER J | Chief Financial Officer | 20,000 0.0369% | $0.89 | $17,872 | +15.04% | ||
| 2024-12-11 | MARIANI PETER J | Chief Financial Officer | 11,363 0.0201% | $0.89 | $10,103 | +15.82% | ||
| 2023-12-13 | Chan Phillip P. | Chief Executive Officer | 75,188 0.129% | $1.33 | $100,000 | -43.89% | ||
| 2023-12-13 | Capponi Vincent | President & COO | 18,797 0.0322% | $1.33 | $25,000 | -43.89% | ||
| 2023-12-13 | BLOCH KATHLEEN P. | Chief Financial Officer | 37,594 0.0645% | $1.33 | $50,000 | -43.89% | ||
| 2023-12-13 | Deliargyris Efthymios | Chief Medical Officer | 22,557 0.0387% | $1.33 | $30,001 | -43.89% | ||
| 2023-12-13 | BATOR MICHAEL G. | director | 37,594 0.0645% | $1.33 | $50,000 | -43.89% | ||
| 2023-12-13 | Sobel Alan D. | director | 22,557 0.0387% | $1.33 | $30,001 | -43.89% | ||
| 2023-12-13 | Jones Edward Raymond | director | 7,519 0.0129% | $1.33 | $10,000 | -43.89% | ||
| 2023-12-13 | Kim Jiny | director | 7,519 0.0129% | $1.33 | $10,000 | -43.89% | ||
| 2023-08-07 | BATOR MICHAEL G. | director | 2,000 0.0046% | $3.17 | $6,350 | -67.31% | ||
| 2023-08-04 | BATOR MICHAEL G. | director | 1,000 0.0023% | $3.23 | $3,230 | -68.13% | ||
| 2023-05-25 | BLOCH KATHLEEN P. | Interim CFO | 3,300 0.0076% | $2.85 | $9,389 | -51.24% | ||
| 2023-05-10 | BLOCH KATHLEEN P. | Interim CFO | 10,000 0.0212% | $3.11 | $31,058 | -53.87% | ||
| 2022-12-08 | Chan Phillip P. | Chief Executive Officer | 5,859 0.0136% | $1.26 | $7,382 | +122.40% | ||
| 2022-12-07 | Chan Phillip P. | Chief Executive Officer | 9,850 0.0221% | $1.26 | $12,411 | +115.50% | ||
| 2022-12-06 | Chan Phillip P. | Chief Executive Officer | 14,291 0.0324% | $1.26 | $18,064 | +117.19% | ||
| 2022-08-25 | Kim Jiny | 1,000 0.0021% | $1.91 | $1,910 | +34.30% | |||
| 2022-06-21 | Capponi Vincent | President and COO | 2,000 0.0047% | $1.80 | $3,600 | +22.73% |
Insider Historical Profitability
| MARIANI PETER J | Chief Financial Officer | 401363 0.732% | $417,417.52 | 3 | 0 | |
| Lamadrid David | Chief Financial Officer | 7837500 14.2942% | $8.15M | 0 | 2 | |
| NJTC INVESTMENT FUND, LP | 10 percent owner | 4870218 8.8824% | $5.07M | 0 | 10 | |
| Chan Phillip P. | Chief Executive Officer | 1068704 1.9491% | $1.11M | 15 | 4 | +29.37% |
| Capponi Vincent | President & COO | 584134 1.0654% | $607,499.36 | 5 | 16 | +12.1% |
| BLOCH KATHLEEN P. | Chief Financial Officer | 467941 0.8534% | $486,658.64 | 15 | 11 | +3.4% |
| Deliargyris Efthymios | Chief Medical Officer | 348433 0.6355% | $362,370.32 | 1 | 0 | <0.0001% |
| Kraus Al | 130046 0.2372% | $135,247.84 | 1 | 52 | +9.68% | |
| BATOR MICHAEL G. | director | 125394 0.2287% | $130,409.76 | 6 | 0 | <0.0001% |
| Sobel Alan D. | director | 101857 0.1858% | $105,931.28 | 2 | 0 | <0.0001% |
| Jones Edward Raymond | director | 88834 0.162% | $92,387.36 | 3 | 0 | +5.37% |
| Kim Jiny | director | 77819 0.1419% | $80,931.76 | 2 | 0 | <0.0001% |
| Mortensen Eric R. | Chief Medical Officer | 2500 0.0046% | $2,600.00 | 1 | 0 | +65.82% |
| BERGER RONALD | See Remarks | 69 0.0001% | $71.58 | 4 | 0 | <0.0001% |
| Gunton James T. | 2 0% | $2.08 | 0 | 10 |
CTSO Institutional Investors: Active Positions
| Increased Positions | 24 | +41.38% | 685,389 | +4.18% |
| Decreased Positions | 20 | -34.48% | 2M | -10.07% |
| New Positions | 11 | New | 293,598 | New |
| Sold Out Positions | 10 | Sold Out | 164,419 | Sold Out |
| Total Postitions | 62 | +6.9% | 15M | -5.89% |
CTSO Ownership Change vs Market
Institutional Investor Ownership
| Avenir Corp | $3,044.00 | 5.63% | 3.09M | +118,387 | +3.98% | 2024-12-31 |
| Skylands Capital, Llc | $2,737.00 | 5.06% | 2.78M | +26,195 | +0.95% | 2024-12-31 |
| Vanguard Group Inc | $1,918.00 | 3.55% | 1.95M | 0 | 0% | 2024-12-31 |
| Neuberger Berman Group Llc | $1,655.00 | 3.06% | 1.68M | -99,477 | -5.58% | 2024-12-31 |
| Sargent Investment Group, Llc | $1,229.00 | 2.27% | 1.25M | -377,384 | -23.21% | 2024-12-31 |
| Granahan Investment Management, Llc | $1,185.00 | 2.19% | 1.2M | -890,302 | -42.5% | 2024-12-31 |
| Cm Management, Llc | $689.00 | 1.27% | 700,000 | -100,000 | -12.5% | 2024-12-31 |
| Blackrock, Inc. | $617.00 | 1.14% | 627,305 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $467.00 | 0.86% | 474,153 | +7,095 | +1.52% | 2024-12-31 |
| Cibc Private Wealth Group Llc | $170.00 | 0.31% | 172,649 | 0 | 0% | 2024-12-31 |